It can be seen from the results that the targeted formulation is localized in the tumor that is overexpressing CA IX after 24 h (Figure 10A–C) compared to the non-targeted formulation (Figure 10D,E) post single i.v. injection. This evidence concerns the gene CA9 and neoplasm.